Abstract
The use of anti-tumour necrosis factor (anti-TNF) therapy is increasing in the treatment of rheumatoid arthritis (RA), spondyloarthropathy, psoriasis and inflammatory bowel disease. It is being debated whether treatment of patients with rheumatic diseases with anti-TNF therapy is associated with an increased cancer incidence.
| Originalsprog | Dansk |
|---|---|
| Tidsskrift | Ugeskrift for Laeger |
| Vol/bind | 171 |
| Udgave nummer | 7 |
| Sider (fra-til) | 506-511 |
| Antal sider | 6 |
| ISSN | 0041-5782 |
| Status | Udgivet - 2009 |
| Udgivet eksternt | Ja |
Emneord
- Adult
- Aged
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Antirheumatic Agents
- Arthritis, Rheumatoid
- Databases, Factual
- Denmark
- Female
- Humans
- Immunoglobulin G
- Male
- Middle Aged
- Neoplasms
- Receptors, Tumor Necrosis Factor
- Registries
- Risk Factors
- Spondylitis, Ankylosing